Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Weill Medical College of Cornell University Millennium Pharmaceuticals, Inc. |
---|---|
Information provided by: | Weill Medical College of Cornell University |
ClinicalTrials.gov Identifier: | NCT00504751 |
Objectives
The primary objective of this study is to:
The secondary objectives of this study are to:
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkin's Lymphoma |
Drug: bortezomib, dexamethasone, ifosfamide Drug: mesna, cisplatin, etoposide, rituximab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Trial of "VIPER" Chemotherapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma (NHL) |
Estimated Enrollment: | 30 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
VIPER chemotherapy will be administered every 28 days at the following doses:
VIPER chemotherapy will be administered every 28 days at the following doses:
Single arm phase II trial of combination therapy bortezomib, DICE, and Rituximab in patients with relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma (NHL)
VIPER chemotherapy will be administered every 28 days at the following doses:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Trish Glynn, RN | 212-746-6738 | pwg2002@med.cornell.edu |
United States, New York | |
Weill Cornell Medical College | Recruiting |
New York, New York, United States, 10021 | |
Contact: Trish Glynn, RN 212-746-6738 | |
Principal Investigator: Richard Furman, MD |
Principal Investigator: | Richard Furman, MD | Weill Cornell Medical College |
Responsible Party: | Weill Cornell Medical College ( Dr. Richard Furman ) |
Study ID Numbers: | 0701008963 |
Study First Received: | July 19, 2007 |
Last Updated: | June 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00504751 History of Changes |
Health Authority: | United States: Institutional Review Board |
diffuse large b cell |
Anti-Inflammatory Agents Dexamethasone Immunologic Factors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Hormones Etoposide phosphate Lymphoma, Small Cleaved-cell, Diffuse Lymphoma, B-Cell Cisplatin Lymphoma, Large-cell Alkylating Agents Lymphoma Etoposide |
Dexamethasone acetate Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders Antineoplastic Agents, Hormonal Rituximab Bortezomib Glucocorticoids Lymphatic Diseases Ifosfamide B-cell Lymphomas Radiation-Sensitizing Agents Mechlorethamine Antineoplastic Agents, Alkylating Peripheral Nervous System Agents Antirheumatic Agents |
Anti-Inflammatory Agents Dexamethasone Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Hormones Cisplatin Therapeutic Uses Alkylating Agents Etoposide Lymphoma Dexamethasone acetate |
Immunoproliferative Disorders Neoplasms by Histologic Type Antineoplastic Agents, Hormonal Immune System Diseases Rituximab Gastrointestinal Agents Glucocorticoids Pharmacologic Actions Lymphatic Diseases Neoplasms Ifosfamide Radiation-Sensitizing Agents Autonomic Agents Antineoplastic Agents, Alkylating Peripheral Nervous System Agents |